MedPath

Rowing Following Breast Cancer Chemotherapy

Not Applicable
Recruiting
Conditions
Breast Cancer Survivors
Interventions
Behavioral: Exercise training
Registration Number
NCT05848141
Lead Sponsor
University of Florida
Brief Summary

There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect of a novel exercise intervention on cardiovascular rehabilitation in breast cancer survivors.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
72
Inclusion Criteria
  • diagnosis of primary invasive non-metastatic breast cancer, stages I-III
  • female based on biological sex
  • 40 to 80 years of age
  • completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation
  • absence of contraindications to exercise or study participation
  • study clinician approval
Exclusion Criteria
  • do not meet inclusion criteria
  • receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation
  • lymphedema stage ≥ 2 prior to study enrolment
  • any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
  • current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
  • consistent participation in ≥150 min/week of moderate-intensity rowing exercise training in previous 6 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Indoor RowingExercise trainingResearch participants will be instructed how to use a Concept 2 RowErg and will be provided instruction on basic rowing skills for beginners. Exercise training will gradually progress to 50 min of moderate-intensity exercise, on 3 days per week, for 12 weeks.
Primary Outcome Measures
NameTimeMethod
% completed vs. planned exercise durationThroughout the 12 weeks of supervised exercise training

We will collect information throughout the exercise intervention regarding % completed vs. planned exercise min/session.

% completed vs. planned exercise intensityThroughout the 12 weeks of supervised exercise training

We will collect information throughout the exercise intervention regarding % completed vs. planned exercise intensity/session.

Change in global longitudinal strainBaseline, Following 12 weeks of supervised exercise training

Global longitudinal strain is a marker of acute subclinical cardiotoxicity and is recommended for monitoring cancer patients at risk of cancer therapy-related cardiac dysfunction.

% completed vs. planned exercise frequencyThroughout the 12 weeks of supervised exercise training

We will collect information throughout the exercise intervention regarding % completed vs. planned exercise sessions/week.

Number of participants who experience adverse event as defined by most recent CTCAEThroughout the 12 weeks of supervised exercise training

To evaluate safety plans are in place for determination and monitoring of adverse events according to the most recent National Cancer Institute Common Terminology Criteria for Adverse Events. Classification for seriousness, expectedness, severity and relationship to study intervention will be based on the NIH provided definitions.

Change in brachial FMDBaseline, Following 12 weeks of supervised exercise training

Flow-mediated dilation (FMD) is an established non-invasive measure of endothelial function. Brachial artery FMD will be determined via ultrasonography in response to reactive hyperemia following 5-min forearm ischemia.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Integrative Cardiovasculal Physiology Laboratory, University of Florida

🇺🇸

Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath